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ABSTRACT
OBJECTIVES
To determine the efficacy and tolerability of β blockers 
in a broad age range of women and men with heart 
failure with reduced ejection fraction (HFrEF) by 
pooling individual patient data from placebo 
controlled randomised trials.
DESIGN
Prospectively designed meta-analysis of individual 
patient data from patients aged 40-85 in sinus rhythm 
at baseline, with left ventricular ejection fraction <0.45.
PARTICIPANTS
13 833 patients from 11 trials; median age 64; 24% 
women.
MAIN OUTCOME MEASURES
The primary outcome was all cause mortality; the major 
secondary outcome was admission to hospital for heart 
failure. Analysis was by intention to treat with an 
adjusted one stage Cox proportional hazards model.
RESULTS
Compared with placebo, β blockers were effective in 
reducing mortality across all ages: hazard ratios were 
0.66 (95% confidence interval 0.53 to 0.83) for the first 
quarter of age distribution (median age 50); 0.71 (0.58 
to 0.87) for the second quarter (median age 60); 0.65 
(0.53 to 0.78) for the third quarter (median age 68); and 
0.77 (0.64 to 0.92) for the fourth quarter (median age 
75). There was no significant interaction when age was 
modelled continuously (P=0.1), and the absolute 
reduction in mortality was 4.3% over a median follow-up 
of 1.3 years (number needed to treat 23). Admission to 
hospital for heart failure was significantly reduced by β 
blockers, although this effect was attenuated at older 
ages (interaction P=0.05). There was no evidence of an 
interaction between treatment effect and sex in any age 
group. Drug discontinuation was similar regardless of 
treatment allocation, age, or sex (14.4% in those give β 
blockers, 15.6% in those receiving placebo).
CONCLUSION
Irrespective of age or sex, patients with HFrEF in sinus 
rhythm should receive β blockers to reduce the risk of 
death and admission to hospital.
REGISTRATION
PROSPERO CRD42014010012; Clinicaltrials.gov 
NCT00832442.
Introduction
β blockers reduce morbidity and mortality in patients 
with heart failure and reduced left ventricular ejection 
fraction and are a cornerstone of modern evidence 
based treatment. Current heart failure guidelines do not 
differentiate treatment on the basis of age or sex, 
although initiation and maintenance of treatment is 
suboptimal both in older people and women.1-3  With 
increasing age, patients are more likely to be women 
(with less marked reduction in left ventricular ejection 
fraction). This interaction, along with relatively low 
numbers of older patients in randomised controlled tri-
als, has created uncertainty about the optimum man-
agement of elderly patients with heart failure and 
reduced ejection fraction (HFrEF), both in women and 
men. Moreover, there are theoretical concerns about 
altered pharmacokinetics in older people that might 
affect the dose required or the tolerability of treat-
ment.4 5  Although subgroup data and the results from 
SENIORS (Study of the Effects of Nebivolol Intervention 
on Outcomes and Rehospitalisation in Seniors with 
Heart Failure) suggest that the efficacy of β blockers is 
retained in older patients,6-8 low uptake and poor main-
tenance of treatment continue to be a clinical reality.
The Beta-blockers in Heart Failure Collaborative Group 
was set up to combine individual patient data from major 
randomised controlled trials in heart failure and provide 
clear direction on clinically relevant  subsets of patients in 
which there is uncertainty about the balance of safety 
and efficacy of β blockers.9 10  Meta-analysis of individual 
patient data allows more robust examination of treat-
ment effects in subgroups and enables of time to event 
analyses adjusted for baseline covariates, making it ideal 
for the appropriate pooling of original data.11  We have 
WHAT IS ALREADY KNOWN ON THIS TOPIC
β blockers can reduce mortality and hospital admission in patients with heart 
failure with reduced ejection fraction and sinus rhythm
Older patients and women often receive less evidence based treatment and often at 
lower doses than shown to be effective in clinical trials
WHAT THIS STUDY ADDS
This study used individual patient data from all major randomised controlled trials 
comparing β blockers with placebo in patients with heart failure with reduced 
ejection fraction and sinus rhythm
In these patients, treatment with β blockers reduced all cause mortality and 
hospital admissions for heart failure, regardless of age or sex, and the tolerability of 
treatment was the same with β blockers and placebo
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previously shown that morbidity and mortality are not 
improved by β blockers in patients with HFrEF and con-
comitant atrial fibrillation, in contrast with patients in 
sinus rhythm, who had substantial reductions in admis-
sion to hospital and all cause mortality.12
In this analysis, we explored the interactions of β 
blocker efficacy and tolerability with age and sex, using 
the largest and most robust dataset of pooled data from 
randomised trials. Our aim was to inform clinicians on 
the appropriate use of these important therapeutic 
agents for patients with HFrEF in sinus rhythm.
Methods
The Beta-blockers in Heart Failure Collaborative Group 
(BB-meta-HF) is a multinational effort, combining individ-
ual data from the major randomised controlled trials 
investigating the use of β blockers in heart failure. The 
group consists of the leading investigators of these trials 
and international experts, with the support of the four 
pharmaceutical companies that conducted the original 
trials (AstraZeneca, GlaxoSmithKline, Merck Serono, and 
Menarini). This report was prepared according to the Pre-
ferred Reporting Items for Systematic reviews and 
Meta-Analyses of individual participant data (PRIS-
MA-IPD) guidelines13  and prospectively registered with 
Clinicaltrials.gov (NCT0083244) and the PROSPERO data-
base of systematic reviews (CRD42014010012).10  Detailed 
rationale and methods have previously been published.9 12
Eligibility, search strategy, and data collection
Published or unpublished randomised controlled trials 
were identified through computer aided searches (for 
example, Medline and Current Contents), scrutiny of 
reference lists of trials, trials registries, meeting 
abstracts, and review articles as well as discussion with 
group members and pharmaceutical manufacturers. 
We included randomised controlled trials that reported 
mortality as a primary outcome or part of a composite 
outcome comparing β blockers versus placebo. Only 
unconfounded head to head trials were eligible, with 
recruitment of over 300 patients and planned follow-up 
of more than six months to make the project technically 
feasible and clinically relevant. The search results, indi-
vidual study demographics and a standardised data 
request form to obtain individual patient data from 
each trial have been published.9
The 11 included studies account for 95.7% of eligible 
participants recruited in randomised controlled trials 
based on a systematic literature review: the Australia/
New Zealand Heart Failure Study (ANZ),14  the Beta-
Blocker Evaluation Survival Trial (BEST),15  the Carve-
dilol Post-Infarct Survival Control in LV Dysfunction 
Study (CAPRICORN),16  the Carvedilol Hibernating 
Reversible Ischaemia Trial: Marker of Success Study 
(CHRISTMAS),17  the Cardiac Insufficiency Bisoprolol 
Study (CIBIS I),18  the Cardiac Insufficiency Bisoprolol 
Study II (CIBIS-II),19  the Carvedilol Prospective Ran-
domised Cumulative Survival Study (COPERNICUS),20 
the Metoprolol in Idiopathic Dilated Cardiomyopathy 
Study (MDC),21  the Metoprolol CR/XL Randomised 
Intervention Trial in Congestive Heart Failure (MER-
IT-HF),22 23  the SENIORS Study,8  and the US Carvedilol 
Heart Failure Study (US-HF).24  All included studies had 
low overall risk of bias, as determined with the 
Cochrane Collaboration’s risk of bias tool.25
Patient involvement
We have insufficient evidence to comment on whether 
patients were actively involved in the design or manage-
ment of these 11 trials.
Outcomes
We extracted data from original source files, and addi-
tional follow-up mortality outcomes were available in 
seven studies. 8 14-16 20 21 24  Our primary outcome was all 
cause mortality, including all reported deaths from 
each component study. Major secondary outcomes 
were all cause mortality during the trial period, all 
reported cardiovascular deaths, admission to hospital 
for heart failure, cardiovascular admission to hospital, 
fatal and non-fatal myocardial infarction, fatal and 
non-fatal stroke, and composites of mortality and hos-
pital admission. One smaller study (1.4% of patients) 
did not  provide data on hospital admission or other 
adverse clinical events,21  though all studies contrib-
uted to the primary outcome (fig 1). Safety outcomes 
focused on discontinuation of study drug treatment 
because of adverse events (hypotension, bradycardia, 
exacerbation of heart failure, renal impairment, and 
respiratory dysfunction). We defined tolerability as the 
dose achieved as a percentage of maximum target 
dose, according to the particular β blocker and specific 
trial design.
Population
Individual patient data were available for 18 637 
patients. For this analysis, restriction to patients with 
HFrEF was prespecified as a left ventricular ejection 
fraction cut off of <0.45, chosen to reflect the era in 
Secondary outcomes
adjusted analysis* (n=13 473)
Primary outcome (all cause mortality)
adjusted analysis (n=13 670)
Included in primary analysis (n=18 637):
  MDC (n=383)
  CIBIS (n=641)
  US-HF (n=1094)
ANZ (n=415)
CIBIS-II (n=2647)
MERIT-HF (n=3991)
COPERNICUS (n=2289)
CAPRICORN (n=1959)
BEST (n=2707)
CHRISTMAS (n=383)
SENIORS (n=2128)
Individual patient data for analysis (n=13 833)
Missing data on covariates for
adjustment in Cox model (n=163)
Excluded from primary analysis (n=4804):
  LVEF ≥0.45 or missing (n=573)
  Atrial brillation, flutter, or paced rhythm
    (n=3638)
  Extremes of age, outside range 40-85
    (n=592)
  Missing follow-up date (n=1)
Fig 1 | Flowchart for included and excluded participants in analysis of effect of age and sex 
on efficacy and tolerability of β blockers in patients with heart failure with reduced 
ejection fraction. LVEF= left ventricular ejection fraction. *MDC trial contributes only to 
mortality outcomes
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which these trials were undertaken, and the cardiac 
imaging distinction that separates patients with moder-
ate and severe left ventricular dysfunction from those 
with mild or “intermediate” reduction in left ventricular 
ejection fraction. In light of our previous findings 
regarding the lack of prognostic benefit of β blockers in 
patients with atrial fibrillation, we evaluated only those 
in sinus rhythm at baseline.12 To improve the robustness 
of the age analysis across the combined dataset, we also 
excluded the 4% of patients at the extremes of age (out-
side the age range of 40-85). One patient in the placebo 
arm was recorded as alive during study visits but had a 
missing final follow-up date and was excluded from 
analysis. Age was primarily assessed as a continuous 
variable, with prespecified division into quarters. Sex 
was explored as a secondary interaction variable across 
the age quarters of the age distribution.
Statistical analysis
Data are presented as percentages or medians and 
interquartile range (IQR; displayed as 25th-75th cen-
tiles). Estimated glomerular filtration rate was calcu-
lated with the modification of diet in renal disease 
(MDRD) formula, normalised to a body surface area of 
1.73 m2. All analyses followed the principle of intention 
to treat. Outcomes were analysed with a stratified Cox 
proportional hazards regression model.26 This is a one 
stage fixed effects approach and assumes that all trials 
are estimating a common treatment effect with baseline 
hazards that vary across studies. Hazard ratios and 95% 
confidence intervals are presented, along with corre-
sponding P values. We prespecified adjustment in Cox 
models for age, sex, previous myocardial infarct, and 
baseline NYHA (New York Heart Association) class 
(I/II v III/IV), left ventricular ejection fraction, heart 
rate, systolic blood pressure, diuretic therapy, and 
angiotensin converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARB). Age was explored 
with numerous non-linear methods, including frac-
tional polynomial models, but the best fit was obtained 
with a linear relation. As the amount of missing data for 
baseline characteristics was minimal, imputation was 
not required. The final population size for the fully 
adjusted Cox model for the primary outcome was 13 670 
(fig 1). We used Kaplan-Meier plots to graph the data 
(pooling data from all trials). As the follow-up periods 
in individual studies varied, data were censored at 1200 
days (3.3 years) from randomisation. Heterogeneity for 
the primary outcome was assessed with χ2 test and I2 
statistic, with the estimate of heterogeneity taken from 
the inverse variance fixed effects two stage model.29  We 
performed a range of predefined sensitivity analyses, 
including alternative censor points, analysis of the 
entire age range, different left ventricular ejection frac-
tion cut offs, exclusion of specific studies, additional 
baseline adjustment, and random effects modelling.28 
Exploratory analyses included a per protocol assess-
ment of patients who remained on study treatment 
throughout the trial. All models showed valid propor-
tional hazards, as determined by Schoenfeld residu-
als.29  Interactions were assessed in all models 
according to best practice.30 31 A two tailed P value of 
0.05 was considered significant. Analyses were per-
formed with Stata version 13.1 (StataCorp LP, TX) and R 
Version 3.0.2 (R Core Team, Vienna).
Results
Age, sex, and baseline characteristics
We included 13 833 HFrEF patients in sinus rhythm in 
the analysis. The median age was 64 (IQR 55-71). Women 
accounted for 24% of patients overall (n=3283) and were 
older than men (66 (58-73) v 63 (55-71); fig A, appendix). 
The median duration of heart failure before enrolment 
was three years (one-six) and median left ventricular 
ejection fraction 0.27 (0.20-0.33). Table 1 shows base-
line demographics according to age; table A in the 
appendix shows baseline demographics by sex.
Primary outcome
Overall 16% of patients died over a median follow-up 
period of 1.3 years (IQR 0.8-1.9). As expected, all cause 
mortality was higher in older patients, with relatively 
higher rates of death from heart failure than in younger 
patients (table B, appendix). Compared with men, 
women had lower absolute rates of all cause mortality 
(14% v 16%), but causes of death were similar (table C, 
appendix).
β blockers significantly reduced all cause mortality 
compared with placebo (968 deaths/7060 (13.7%) v 
1222/6773 (18.0%)). The relative risk reduction with β 
blockers was 24%, with an absolute risk reduction of 
4.3% (number needed to treat 23, 95% confidence inter-
val 18 to 32). The adjusted hazard ratio was 0.70 (95% 
confidence interval 0.64 to 0.77); P<0.001). Figure 2 
shows the primary age analysis, assessing the hazard of 
death for β blockers compared with placebo across the 
range of age, modelled as a continuous variable. No sta-
tistical interaction with age was identified (P=0.1 for 
interaction). Table 2  displays the hazard ratio and fig-
ure 3  the Kaplan-Meier plots for each age quarter, con-
firming efficacy for the primary outcome in all quarters, 
including the oldest patients. Similar absolute risk 
reductions with β blockers were noted in all age quarters 
(table D in appendix). β blockers were effective in both 
women and men, in the whole group, and within spe-
cific age quarters (table 2  and fig 4). All sensitivity anal-
ysis for the primary outcome identified similar results to 
the main statistical model (table E in appendix).
Secondary outcomes
There was attenuation of the benefits of β blockers on 
cardiovascular death by age (P=0.04 for interaction) but 
there remained a significant reduction in events even in 
the oldest age group (table 3 ). Similar findings were 
seen with hospital admission for heart failure (fig 3  and 
table D in appendix), cardiovascular hospital admis-
sion and composite clinical outcomes. Fatal and 
 non- fatal myocardial infarct or stroke were not reduced 
with β blockers in the whole group nor in any age quar-
tile (table 2 ). For all of the secondary outcomes, the 
effect in women and men were similar, with no interac-
tion identified according to gender (table 2  and fig 4).
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Table 3 provides date on hospital admissions related 
to cardiovascular, events, all causes, and heart failure, 
divided by quarters of the age distribution and sex. 
Admission rates increased with age and were similar in 
both sexes. In the oldest quarter of age, patients had 
more than one admission per year, with half of these 
admissions because of heart failure, and a median 
length of stay of seven days in hospital.
Tolerability of therapy
There were similar rates of discontinuation because of 
adverse events in the placebo and β blocker arms across 
quarters of the age distribution and sex, although these 
increased slightly with age (table 4). Overall, a numeri-
cally lower number of patients discontinued β blockers 
(14.4% v 15.6% in placebo). Table F in the appendix 
shows specific causes of β blocker discontinuation 
according to age and sex. Small numbers of patients 
discontinued treatment because of hypotension (0.7-
1.6%), bradycardia (0-3.5%), exacerbation of heart fail-
ure (2.0-4.9%), renal impairment (0-1.2%), and 
respiratory compromise (0.5-1.2%). Discontinuation 
was similar across age and sex, apart from a small 
excess in exacerbation of heart failure in the youngest 
age quarter for women compared with men (5.4% v 
2.2%) and in bradycardia in the oldest men (3.5% v 0.7% 
in the oldest women). Dose of β blocker did not differ 
across age and sex, with patients attaining 73% of the 
target dose at the interim study point (table G in appen-
dix) compared with 84% achieving the corresponding 
dose of placebo.
Discussion
Principal findings
Using the near totality of available data from ran-
domised controlled trials of β blockers in patients with 
heart failure with reduced ejection fraction (HFrEF) 
and sinus rhythm, our analysis shows that there is no 
evidence of a clinically significant interaction with age 
or sex with respect to all cause mortality. We observed 
a significant benefit from β blockers in each quarter of 
the age distribution, with absolute reductions in mor-
tality of about 4% in the youngest and oldest patients. 
Results for hospital admission related to heart failure 
were similar, with significant reductions in each age 
quarter, albeit with minor attenuation of treatment 
effect in older patients. Discontinuation of treatment 
was similar in patients randomised to β blockers or pla-
cebo, even in older patients, suggesting that “intoler-
ance” of β blockers in clinical practice could reflect false 
attribution to intercurrent events or preconceptions 
about side effects.
Age (years)
Ha
za
rd
 ra
tio
40 50 60 70 80
0.4
0.6
0.8
1.0
1.2
1.6
1.4
Hazard ratio
95% CI
Hazard ratio and 95% CI
for age quarter
Fig 2 | β blockers versus placebo hazard model for all cause 
mortality and age. Hazard ratio for β blockers compared 
with placebo in HFrEF patients with sinus rhythm. Age 
modelled as continuous variable, with results for each 
quarter superimposed
Table 1 | Baseline characteristics* in patients with heart failure with reduced ejection fraction and sinus rhythm by quarter of age distribution. Figures 
are number (percentage) unless stated otherwise
Characteristic
Quarter 1 (youngest) 
(n=3458)
Quarter 2 
(n=3590)
Quarter 3 
(n=3327)
Quarter 4 (oldest) 
(n=3458)
Median (IQR) age (years) 50 (46-53) 60 (58-62) 68 (66-70) 75 (73-78)
Women 639 (18%) 764 (21%) 794 (24%) 1086 (31%)
Ischaemic heart failure aetiology 1856 (54%) 2478 (69%) 2544 (76%) 2798 (81%)
Previous myocardial infarction 1648 (48%) 2158 (60%) 2190 (66%) 2287 (66%)
Previous coronary revascularization 592 (18%) 785 (24%) 769 (25%) 753 (23%)
Diabetes mellitus 681 (21%) 892 (27%) 833 (27%) 897 (26%)
Median (IQR) years with heart failure diagnosis 2 (1-5) 3 (1-6) 3 (1-7) 3 (1-6)
Median (IQR) LVEF 0.25 (0.20-0.32) 0.26 (0.20-0.32) 0.27 (0.21-0.32) 0.29 (0.22-0.34)
NYHA class III/IV 2359 (68%) 2440 (68%) 2285 (69%) 2081 (61%)
Median (IQR) systolic BP (mm Hg) 120 (110-130) 120 (110-136) 126 (113-140) 130 (115-142)
Median (IQR) diastolic BP (mm Hg) 78 (70-84) 78 (70-83) 77 (70-80) 75 (69-80)
Median (IQR) heart rate (bpm) 82 (74-91) 80 (72-88) 78 (72-86) 77 (70-85)
Median (IQR) BMI 28 (25-33) 27 (25-31) 27 (24-30) 26 (24-29)
Median (IQR) estimated GFR (mL/min) 73 (61-86) 66 (54-79) 59 (48-71) 55 (44-67)
Any diuretic therapy 2896 (84%) 3055 (85%) 2859 (86%) 3000 (87%)
ACEi or ARB 3332 (96%) 3410 (95%) 3154 (95%) 3207 (93%)
Aldosterone antagonists 255 (8%) 188 (6%) 256 (8%) 369 (11%)
Digoxin 2090 (62%) 1956 (56%) 1652 (51%) 1504 (44%)
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; BP=blood pressure; BMI=body mass index; GFR=glomerular filtration rate; IQR=interquartile range; LVEF=left 
ventricular ejection fraction; NYHA=New York Heart Association functional class.
*Missing data (total across all quarters): previous myocardial infarction n=30; previous coronary revascularisation n=900; diabetes mellitus n=809; years with heart failure diagnosis n=2817; 
systolic BP n=59; diastolic BP n=65; heart rate n=8; BMI n=128; GFR n=662; NYHA n=73; diuretics n=1; aldosterone antagonists n=890; digoxin n=348.
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Clinical context: age
Heart failure guidelines recommend β blockers for 
patients with HFrEF but have not previously been able 
to exclude an interaction with age.32 33  As a result, pre-
scription of treatment and long term continuation have 
been lower in older patients,34-36  presumably as clini-
cians trade off a perceived lower efficacy with other con-
siderations such as potential adverse events and 
polypharmacy. The proportion of patients in our analy-
sis aged >70 was 30%, which does not reflect the “real 
world” population of HFrEF. In the three largest US 
heart failure registries (ADHERE, OPTIMIZE-HF, and Get 
With The Guidelines), the average age of patients with 
HFrEF was 70 (SD 14 and 14 and IQR 58-80, respectively; 
total 101 066 patients).37  Similarly, in the Swedish Heart 
Failure Registry of 21 864 patients with HFrEF, the mean 
age was 72 (SD 12).38  This confirms that older patients 
are under-represented in randomised controlled trials 
in heart failure, necessitating the pooling of data to pro-
vide information on treatment efficacy. In this context, 
individual patient data provide the only robust method 
to adequately combine subgroup data.39
There are important demographic changes noted with 
advancing age. Compared with the youngest quarter, 
older patients were more often women (31% v 18%) and 
had more ischaemic aetiology (81% v 54%), higher left 
ventricular ejection fraction (0.29 v 0.25), higher systolic 
blood pressure (130 mm Hg v 20 mm Hg), lower heart rate 
(77 v 82 beats/min), and reduced kidney function (55 v 73 
mL/min) and fewer received digoxin (44% v 62%). These 
factors are known to affect prognosis in heart failure in 
different ways. Age is the most powerful predictor of 
prognosis but is not itself a predictor of response to treat-
ment. The higher systolic blood pressure, higher left ven-
tricular ejection fraction, and lower heart rate observed 
in older patients are predictors of better prognosis, while 
chronic renal impairment is associated with poor prog-
nosis. The median length of heart failure before the trial 
was two years in the lowest age quarter and three years in 
the other age quarters, suggesting that patients were 
entered into the trials at a similar time after initial diag-
nosis, irrespective of age. Type of death also differed 
between age groups. Half of deaths in the youngest quar-
ter are classified as “sudden” compared with 34% in the 
oldest quarter, whereas deaths from heart failure 
accounted for 16% compared with 31%, respectively. 
Thus the heterogeneity in age in the trials also reflects 
heterogeneity in aetiology of heart failure and comorbid-
ity patterns. The results of this individual patient data 
meta-analysis, showing the clear benefit of β blockers 
across all age groups despite this heterogeneity, is an 
important finding that cannot be predicted by analysis of 
patient characteristics and outcomes in observational 
datasets or mechanistic studies. Our assessment con-
firms that irrespective of different patient factors associ-
ated with age, patients in sinus rhythm benefit from 
treatment with a β blocker, a novel and important finding 
that informs clinical practice and underpins the applica-
bility of current clinical guidelines.32 33
In general, the effect of β blockers was consistent on 
the major secondary outcomes analysed. We did identify T
ab
le
 2
 | H
az
ar
d 
ra
tio
s f
or
 p
rim
ar
y a
nd
 se
co
nd
ar
y o
ut
co
m
es
 in
 p
at
ie
nt
s w
ith
 h
ea
rt 
fa
ilu
re
 w
ith
 re
du
ce
d 
ej
ec
tio
n 
fra
ct
io
n 
an
d 
si
nu
s r
hy
th
m
 b
y q
ua
rte
r o
f a
ge
 d
is
tri
bu
tio
n*
β 
bl
oc
ke
rs
 v 
pl
ac
eb
o/
ou
tc
om
e†
P 
va
lu
e 
fo
r a
ge
 
(c
on
tin
uo
us
) 
in
te
ra
ct
io
n
HR
 (9
5%
 C
I)
Qu
ar
te
r 1
 
(y
ou
ng
es
t)
P 
va
lu
e‡
Qu
ar
te
r 2
P 
va
lu
e‡
Qu
ar
te
r 3
P 
va
lu
e‡
Qu
ar
te
r 4
 (o
ld
es
t)
P 
va
lu
e‡
Al
l c
au
se
 m
or
ta
lit
y (
pr
im
ar
y o
ut
co
m
e)
0.
10
0.
66
 (0
.5
3 
to
 0
.8
3)
0.
70
0.
71
 (0
.5
8 
to
 0
.8
7)
0.
66
0.
65
 (0
.5
3 
to
 0
.7
8)
0.
09
0.
77
 (0
.6
4 
to
 0
.9
2)
0.
54
Al
l c
au
se
 m
or
ta
lit
y (
du
rin
g 
st
ud
y p
er
io
d 
on
ly)
0.
08
0.
62
 (0
.4
8 
to
 0
.7
8)
0.
74
0.
72
 (0
.5
8 
to
 0
.8
8)
0.
80
0.
64
 (0
.5
2 
to
 0
.7
8)
0.
09
0.
77
 (0
.6
4 
to
 0
.9
3)
0.
40
Ca
rd
io
va
sc
ul
ar
 d
ea
th
0.
04
0.
66
 (0
.5
2 
to
 0
.8
4)
0.
46
0.
70
 (0
.5
6 
to
 0
.8
7)
0.
57
0.
59
 (0
.4
7 
to
 0
.7
3)
0.
07
0.
81
 (0
.6
6 
to
 0
.9
9)
0.
43
Fi
rs
t a
dm
is
si
on
 re
la
te
d 
to
 h
ea
rt 
fa
ilu
re
0.
05
0.
59
 (0
.4
 to
 0
.74
)
0.
64
0.
65
 (0
.5
4 
to
 0
.7
8)
0.
54
0.
68
 (0
.5
6)
 to
 0
.8
3)
0.
86
0.
78
 (0
.6
4 
to
 0
.9
4)
0.
74
Fi
rs
t a
dm
is
si
on
 re
la
te
d 
to
 C
V 
ev
en
t
0.
04
0.
65
 (0
.5
5 
to
 0
.7
7)
0.
38
0.
78
 (0
.6
8 
to
 0
.9
1)
0.
70
0.
74
 (0
.6
4 
to
 0
.8
7)
0.
99
0.
92
 (0
.8
0 
to
 1.
07
)
0.
15
De
at
h 
or
 a
dm
is
si
on
 fo
r a
dm
is
si
on
 fo
r c
ar
di
ov
as
cu
la
r e
ve
nt
0.
03
0.
66
 (0
.5
7 
to
 0
.7
7)
0.
64
0.
78
 (0
.6
8 
to
 0
.8
9)
0.
46
0.
73
 (0
.6
4 
to
 0
.8
4)
0.
91
0.
87
 (0
.7
7 
to
 1.
00
)
0.
07
Ca
rd
io
va
sc
ul
ar
 d
ea
th
 o
r a
dm
is
si
on
 fo
r h
ea
rt 
fa
ilu
re
0.
03
0.
66
 (0
.5
6 
to
 0
.7
7)
0.
79
0.
78
 (0
.6
8 
to
 0
.8
9)
0.
52
0.
72
 (0
.6
2 
to
 0
.8
2)
0.
98
0.
89
 (0
.7
8 
to
 1.
02
)
0.
08
Fa
ta
l a
nd
 n
on
-fa
ta
l M
I
0.
10
0.
66
 (0
.3
9 
to
 1.
09
)
0.
16
0.
64
 (0
.4
3 
to
 0
.9
8)
0.
46
0.
73
 (0
.4
6 
to
 1.
14
)
0.
98
0.
94
 (0
.6
3 
to
 1.
42
)
0.
50
Fa
ta
l a
nd
 n
on
-fa
ta
l s
tro
ke
0.
55
0.
73
 (0
.3
4 
to
 1.
56
)
0.
66
1.2
1 
(0
.6
5 
to
 2
.2
5)
0.
62
1.0
0 
(0
.5
5 
to
 1.
84
)
0.
96
1.1
1 
(0
.6
5 
to
 1.
90
)
0.
65
M
I=
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n.
*A
na
ly
se
d 
w
ith
 o
ne
 s
ta
ge
 C
ox
 re
gr
es
si
on
 m
od
el
, w
ith
 s
tu
di
es
 a
s s
tra
ta
 (c
en
so
r 1
20
0 
da
ys
); 
ad
ju
st
ed
 fo
r a
ge
, s
ex
, m
yo
ca
rd
ia
l i
nf
ar
ct
, N
YH
A 
cl
as
s (
I/I
I v
 II
I/I
V)
, L
VE
F, 
he
ar
t r
at
e,
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e 
an
d 
ba
se
lin
e 
AC
Ei
/A
RB
, a
nd
 d
iu
re
tic
 tr
ea
tm
en
t. 
Se
x 
in
te
ra
ct
io
n 
P 
va
lu
es
 a
re
 g
iv
en
 fo
r t
re
at
m
en
t a
llo
ca
tio
n 
an
d 
se
x w
ith
in
 e
ac
h 
ag
e 
qu
ar
te
r.
†M
DC
 tr
ia
l c
on
tri
bu
te
s o
nl
y t
o 
m
or
ta
lit
y o
ut
co
m
es
.
‡F
or
 in
te
ra
ct
io
n 
w
ith
 s
ex
.
 o
n
 19 Septem
ber 2019 at St G
eorge's, University of London. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.i1855 on 20 April 2016. Downloaded from 
RESEARCH
doi: 10.1136/bmj.i1855 | BMJ 2016;353:i1855 | the bmj6
YearsNumbers at risk
Placebo
β blocker
Pr
op
or
tio
n 
wi
th
 e
ve
nt
Quarter 1: median age 50 (IQR 46-53)
All cause mortality
0 1 2 3 4
0
0.1
0.2
0.3
0.4
0.5
ARR=4.0%
NNT=25
Log rank P<0.001
Placebo
β blocker
Years
Quarter 2: median age 60 (IQR 58-62)
0 1 2 3 4
1630
1668
840
976
213
282
71
95
1701
1756
976
1054
281
314
56
69
Numbers at risk
Placebo
β blocker
1627
1719
930
1114
269
402
100
181
1713
1814
967
1111
262
358
72
133
ARR=3.4%
NNT=29
Log rank P<0.001
Pr
op
or
tio
n 
wi
th
 e
ve
nt
Quarter 3: median age 68 (IQR 66-70)
0
0.1
0.2
0.3
0.4
0.5
ARR=5.5%
NNT=18
Log rank P<0.001
Quarter 4: median age 75 (IQR 73-78)
ARR=4.4%
NNT=23
Log rank P<0.001
Pr
op
or
tio
n 
wi
th
 e
ve
nt
Quarter 1: median age 50 (IQR 46-53)
Hospital admission for heart failure
0
0.1
0.2
0.3
0.4
0.5
ARR=6.2%
NNT=16
Log rank P<0.001
Numbers at risk
Placebo
β blocker
1645
1682
1011
1087
285
343
102
121
1702
1756
1104
1183
331
363
76
86
Numbers at risk
Placebo
β blocker
1682
1776
1117
1263
407
517
183
261
1743
1846
1129
1238
353
441
127
187
Quarter 2: median age 60 (IQR 58-62)
ARR=5.1%
NNT=20
Log rank P<0.001
Pr
op
or
tio
n 
wi
th
 e
ve
nt
Quarter 3: median age 68 (IQR 66-70)
0
0.1
0.2
0.3
0.4
0.5
ARR=6.8%
NNT=15
Log rank P<0.001
Quarter 4: median age 75 (IQR 73-78)
ARR=2.9%
NNT=34
Log rank P<0.02
Fig 3 | Kaplan-Meier event 
curves according to quarter 
of age distribution for 
primary outcome (all cause 
mortality) and major 
secondary outcome 
(admission for heart failure) 
for β blockers v placebo by 
age. ARR=absolute risk 
reduction; NNT=number 
needed to treat
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attenuated prevention of hospital admission by β block-
ers with age (P=0.05 for first hospital admission related 
to heart failure and P=0.04 for first admission related to 
cardiovascular event). Adjusted hazard ratios, however, 
remained significant across age quarters and for all out-
comes, apart from two secondary outcomes (hospital 
admission for cardiovascular event and the composite 
of cardiovascular death or admission for heart failure). 
Reassuringly, we did not identify differences in hospital 
admissions related to heart failure according to age or 
sex, and the length of hospital stay was similar in all 
patients, regardless of age or sex.
Clinical context: sex
Baseline demographics show that women with heart 
failure entered into randomised controlled trials tend to 
be older than men and differences such as higher sys-
tolic blood pressure, higher left ventricular ejection 
fraction, and lower estimated glomerular filtration rate 
might simply reflect this age difference. Women have a 
lower incidence of ischaemic aetiology and previous 
myocardial infarct, although a similar prevalence of 
heart failure compared with men.40  Prognosis has been 
shown to be better in women, though mortality rates are 
still 25% over three years.41  Previous subgroup data 
from randomised controlled trials have provided con-
flicting results about the efficacy of β blockers in 
women, including equal benefit (for example the MER-
IT-HF and CIBIS trials),42 43  enhanced mortality reduc-
tion compared with men (US Heart Failure trial),24  and 
also no effectiveness in women (BEST trial).44  Our 
results confirm that there is no difference in β blocker 
efficacy in HFrEF according to sex. Cause of death in 
women and men showed identical proportions and pat-
terns for sudden, heart failure, and non-cardiovascular 
deaths, which further support the concordance for 
 recommendation of β blockers. Thus, treatment with β 
blockers should not be withheld from women with 
HFrEF, a practice that has been reported alongside 
fewer cardiology assessments and cardiac procedures.45 
Women were under-represented in the clinical trials we 
analysed (24%), and this continues to be the case—for 
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Fig 4 | Kaplan-Meier event curves according to sex for primary 
outcome (all cause mortality) and major secondary outcome 
(admission for heart failure) for β blockers v placebo by sex. 
ARR=absolute risk reduction; NNT=number needed to treat
Table 3 | Admission to hospital in patients with heart failure with reduced ejection fraction and sinus rhythm by quarter of age distribution
Admission type
Quarter 1 (youngest) Quarter 2 Quarter 3 Quarter 4 (oldest) All ages
Women Men Women Men Women Men Women Men Women Men
All cause
% with ≥1 admission 39% 31% 35% 36% 39% 40% 40% 43% 39% 37%
Average No (range) of admissions 0.94 (0-18) 0.67 (0-18) 0.78 (0-14) 0.76 (0-22) 0.79 (0-11) 0.79 (0-17) 0.68 (0-12) 0.85 (0-26) 0.78 (0-18) 0.76 (0-26)
Annualised rate/patient 0.67 0.69 0.85 0.81 0.87 0.86 1.05 1.06 0.85 0.85
Cardiovascular
% with ≥1 admission 25% 20% 23% 25% 27% 27% 28% 30% 26% 25%
Average No (range) of admissions 0.48 (0-13) 0.38 (0-14) 0.44 (0-13) 0.46 (0-16) 0.47 (0-10) 0.46 (0-10) 0.43 (0-12) 0.50 (0-16) 0.45 (0-13) 0.44 (0-16)
Annualised rate/patient 0.36 0.38 0.47 0.45 0.56 0.57 0.67 0.67 0.51 0.51
Average (IQR) length of stay (days)* 6 (3-9) 6 (3-10) 6 (3-9) 6 (3-12) 7 (3-11) 6 (4-11) 7 (3-11) 6 (3-12) 6 (3-11) 6 (3-11)
Related to heart failure
% with ≥1 admission 19% 13% 16% 17% 17% 17% 16% 19% 17% 16%
Average No (range) of admissions 0.36 (0-7) 0.25 (0-12) 0.32 (0-13) 0.31 (0-16) 0.29 (0-10) 0.29 (0-10) 0.25 (0-12) 0.32 (0-16) 0.30 (0-13) 0.29 (0-16)
Annualised rate/patient 0.24 0.27 0.32 0.30 0.33 0.35 0.46 0.45 0.34 0.34
Average (IQR) length of stay (days)* 6 (3-10) 6 (4-11) 7 (4-10) 7 (4-13) 7 (4-12) 7 (4-12) 7 (4-12) 6 (4-11) 7 (4-11) 7 (4-12)
*Based on first five hospital admissions for cardiovascular/heart failure cause. MDC trial does not contribute to admission outcomes.
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example, in the recent large randomised controlled trial 
of angiotensin-neprilysin inhibition versus enalapril in 
HFrEF, women accounted for only 22% of the patients 
recruited.46 There is a clear need to improve the enrol-
ment of women to provide realistic expectations of their 
risk and benefit from treatment.
Side effects and tolerability
Importantly for all ages and both sexes, we identified 
low rates of discontinuation of β blockers because of 
adverse events and similar withdrawal rates to pla-
cebo. Although β blockers are often associated with 
side effects, data from randomised trials consistently 
show no true difference compared with placebo in 
dizziness, diarrhoea, increased blood sugar concen-
tration, or depression and little or no increase in leth-
argy with modern generation β blockers.47-49 This 
information should reassure clinicians about the tol-
erability of β blockers in view of the prognostic bene-
fit we have identified in women and elderly people of 
both sexes. Elderly patients were able to reach simi-
lar maximal dose compared with younger patients 
with HFrEF.
Strengths and limitations of study
It is plausible that the benefits of β blockers are attenu-
ated in very old people (aged >80), although the amount 
of information on these patients from existing ran-
domised controlled trials is scarce. Extrapolation from 
figure 2  indicates that any attenuation of prognostic 
benefit with age is actually quite mild and the effect of β 
blockers in patients aged >80 will still be associated 
with hazard ratios of around 0.8 (giving a worthwhile 
20% proportional reduction in the average risk of 
death). In the extreme elderly, it is worth noting that 
there are competing mortality risks. Even with pooling 
of individual patient data from all large datasets, there 
are limitations to inference of treatment effects in sub-
groups. Examination of treatment interactions by age 
shows significant treatment benefits in each age group, 
but assessment of interactions of age and sex will be 
limited by the size of the groups, number of events, and 
inclusion criteria for the component studies. For exam-
ple, a lack of interaction might not provide full informa-
tion on treatment effects in very elderly women because 
of the atypical elderly cohort included in the original 
trials. We specifically included only patients with HFrEF 
in sinus rhythm at baseline. Although sensitivity analy-
ses including all patients showed a similar lack of inter-
action with age or sex, direct extrapolation to patients 
with left ventricular ejection fraction >0.45 cannot be 
made. Similarly, we have previously reported on out-
comes for β blockers in patients with concomitant heart 
failure and atrial fibrillation,12  and, although these 
patients have poor prognosis,50  they are distinctly dif-
ferent to patients with heart failure in sinus rhythm and 
require specific management.51
There have been changes in risk factor profiles and 
treatment patterns since the component studies were 
completed (for example, the use of cardiac resynchro-
nisation treatment), however, β blockers are still a 
vital component of optimal care in these patients52 
and might have a synergistic effect (for example, with 
mineralocorticoid receptor antagonists).53  Finally, as 
with all meta-analytical techniques, we are limited by 
the data provided from the individual studies, with 
the inherent heterogeneity of patient populations. 
The strength of our analysis was the use of individual 
patient data from high quality randomised controlled 
trials, with near totality of available data and method-
ical data extraction from original datasets,9 resulting 
in improved quality of outcome data across trials.
Conclusions and policy implications
This analysis confirms that treatment with β blockers 
reduces mortality and hospital admissions related to 
heart failure in patients with HFrEF with sinus rhythm, 
irrespective of age or sex. Absolute effect sizes for all 
cause mortality were similar across age quarters with 
no significant interaction when we used an adjusted 
continuous hazard model. In addition, the tolerability 
of β blockers was similar to placebo, reinforcing the use 
of β blockers in all patients with HFrEF in sinus rhythm 
and discouraging the practice of withholding such 
treatment in women or elderly patients.
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